Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells

G. Sica, G. Lama, F. Iacopino, C. Angelucci, G. Robustelli Della Cuna, P. Marchetti

Research output: Contribution to journalArticle

Abstract

The effect of Lonidamine (LND) alone or combined with the antiestrogen Tamoxifen (TAM) or Medroxyprogesterone acetate (MPA) on cell proliferation and steroid hormone receptor content of a human estrogen sensitive breast cancer cell line was investigated. LND has a direct growth inhibitory action, even if used at relatively low concentrations (10-7M), and shows the maximum effect at 10-4M. The combination of LND with the antiestrogen does not produce a potentiation of the TAM-induced reduction of cell number, while the association of the drug with MPA seems more effective with respect to MPA alone, at least at certain concentrations. The negative interference observed between LND and TAM may be due to the LND-induced decrease of estrogen receptor levels.

Original languageEnglish
Pages (from-to)2099-2102
Number of pages4
JournalAnticancer Research
Volume11
Issue number6
Publication statusPublished - 1991

Keywords

  • Acetate
  • Breast cancer cells
  • Lonidamine
  • Medroxyprogesterone
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells'. Together they form a unique fingerprint.

Cite this